Johnson & Johnson (J&J) has proposed a $5.5 billion settlement to resolve tens of thousands of lawsuits in the United States alleging its baby powder and other talc-based products caused ovarian cancer. The settlement. If accepted by legal firms representing 95% of the claimants in state and federal courts, would cover 99.75% of all outstanding talc-related cases in the country, according to BBC and Al Jazeera.

Legal and Financial Breakdown of the Settlement

J&J will pay up to $3 billion in 2025, with no additional payments required before 2028, according to the company; the proposed settlement does not cover the United Kingdom, where a major product liability case involving over 7,000 claimants is still ongoing. Erik Haas. J&J’s litigation head. Stated the agreement allows the company to “put this matter behind it” and remain focused on its core mission of developing medicines and devices.

J&J has denied that its talc-based products cause cancer and has changed the formula of its baby powder, while the company stopped selling talc-based baby powder in the U.S. in 2020 and worldwide in 2023. Its former consumer health business, Kenvue, holds liability for talc-related claims outside North America.

Historical Context and Legal Precedent

Lawsuits against J&J over talc-based baby powder date back to 2009. In 2016. A U.S. jury ordered J&J to pay $72 million to the family of a woman who died of ovarian cancer, the first such case in the country. Though that case was overturned in 2017, claims against the company continued to mount, with juries across the U.S. awarding plaintiffs in subsequent cases.

In 2024. The World Health Organization classified talc as “probably carcinogenic to humans.” Talc, a natural mineral composed of magnesium, silicon, oxygen, and hydrogen, was widely used in cosmetics and baby products but its use has declined as concerns over cancer risk grew. In July. A federal court questioned whether individual plaintiffs could prove talc was the direct cause of ovarian cancer, according to BBC.

Financial Performance and Investor Outlook

While the legal settlement dominates headlines, J&J’s financial performance in its pharmaceuticals division has been strong. TREMFYA, one of its key drugs, reported $2 billion in revenue for the quarter ending June 2026, a 71% increase year-over-year. Analysts are optimistic about the stock, with 22 analysts covering J&J, including 11 recommending a buy and an average price target of $271, according to TIKR.com.

J&J’s shares are trading near recent highs, only 1.44% below the peak. While the company faces financial and reputational challenges from the talc lawsuits, its pharmaceuticals division has shown resilience and growth, offering investors a potential offset to legal costs.